circRNA circ-MYBL2 is a novel tumor suppressor and potential biomarker in multiple myeloma

Yu, Shanshan; Ai, Limei; Wei, Wei; Pan, Jing

doi:10.1007/s13577-020-00441-8

Cited by 23 publications

(16 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, circ-MYBL2 also suppresses the transcription of multiple oncogenes, suggesting its role as a tumor suppressor in multiple myeloma. 14 In contrast, upregulation of circ-MYBL2 has been observed in cervical cancer, and circ-MYBL2 can sponge miR-361-3p to promote cancer cell invasion and proliferation. 15 We analyzed the differential expression of circ-MYBL2 in NSCLC and observed its downregulation in cancer tissues.…”

Section: Discussionmentioning

confidence: 99%

“…The functions of circ-MYBL2 have been investigated in myeloma and cervical cancers, and opposite roles of circ-MYBL2 were observed in these two cancers. 14 , 15 Circ-MYBL2 is downregulated in multiple myeloma and overexpression of circ-MYBL2 suppressed cancer cell mobility and cell cycle progression. In addition, circ-MYBL2 also suppresses the transcription of multiple oncogenes, suggesting its role as a tumor suppressor in multiple myeloma.…”

Section: Discussionmentioning

confidence: 99%

“…This study was carried out to explore the role of circ-MYBL2 in NSCLC. 14 , 15 We predicted that circ-MYBL2 could interact with miR-28, which promotes lung cancer. 16 We then studied the crosstalk between circ-MYBL2 and miR-28 in NSCLC.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

A Cytoplasm-Enriched circRNA circ-MYBL2 is Downregulated in Non-Small Cell Lung Cancer and Sponges Oncogenic miR-28 to Regulate Cancer Cell Proliferation and Apoptosis

Mao

Wang

2021

CMAR

View full text Add to dashboard Cite

Background Recent studies have reported different roles of circRNA circ-MYBL2 in different cancers. However, the involvement of circ-MYBL2 in non-small cell lung cancer (NSCLC) is unknown. This study was carried out to explore the role of circ-MYBL2 in NSCLC. Methods The expression of circ-MYBL2 and miR-28 was detected by RT-qPCR. A 5-year follow-up study was performed for survival analysis. Nuclear fractionation assay was used for subcellular localization analysis. RNA pull-down assay was performed to detect the interaction between circ-MYBL2 and miR-28. The role of circ-MYBL2 and miR-28 in regulating the expression of each other was evaluated by overexpression assay. BrdU incorporation assay and cell apoptosis assay were performed to investigate the role of circ-MYBL2 and miR-28 in cell proliferation and apoptosis. Results NSCLC tissues exhibited significantly higher expression levels of miR-28 and lower expression levels of circ-MYBL2. Close correlations between circ-MYBL2 and miR-28 and patients’ survival were observed. Circ-MYBL2, which was found to be mainly enriched in cytoplasm, directly interacted with miR-28. Although circ-MYBL2 and miR-28 showed no regulatory role in the expression of each other, circ-MYBL2 suppressed the effects of miR-28 on cell proliferation and apoptosis. Conclusion Circ-MYBL2 is enriched in cytoplasm, and it sponges oncogenic miR-28 to suppress cancer cell proliferation in NSCLC and promote cell apoptosis.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

A Cytoplasm-Enriched circRNA circ-MYBL2 is Downregulated in Non-Small Cell Lung Cancer and Sponges Oncogenic miR-28 to Regulate Cancer Cell Proliferation and Apoptosis

Mao

Wang

2021

CMAR

View full text Add to dashboard Cite

show abstract

“…Some cir-cRNAs have been reported as new diagnostic biomarkers, effective prognosticators, and promising therapeutic targets in human cancers including multiple myeloma [19,20]. For example, Yu et al found that circRNA circ_MYBL2 is a novel tumor suppressor and potential biomarker in multiple myeloma [21]. Song et al indicated that circRNA circ_0007841 is upregulated in multiple myeloma, and may act as a novel potential biomarker and drug resistance for multiple myeloma [22].…”

Section: Discussionmentioning

confidence: 99%

CircRNA circ_0001821 predicts an unfavorable prognosis and promotes the proliferation of multiple myeloma

Liu

Zhang

2021

Hematology

View full text Add to dashboard Cite

Background: A previous study reported circ_0001821 serves as a new diagnostic biomarker in lung and gastric cancer. However, whether circ_0001821 associates with the development of multiple myeloma is still unclear. Objective: To investigate the clinical significance and biological function of circ_0001821 in human multiple myeloma. Methods: The expression of circ_0001821 in bone marrow tissues and cell lines of multiple myeloma was detected by quantitative real-time PCR. The relationship between circ_0001821 expression and clinicopathological characteristics in multiple myeloma patients was determined by the Chi-square test. MTT, Western blotting analysis and flow cytometry were performed to evaluate the impact of circ_0001821 on cell proliferation and apoptosis. Results: Circ_0001821 expression was increased in bone marrow tissues and cell lines from multiple myeloma compared with that in normal controls, and its expression was related to hemoglobin, bone injury, β2-MG, and globulin. In multiple myeloma patients aged ≥60 years, high circ_0001821 expression displayed lower overall survival (OS) rate compared with low circ_0001821 expression. High circ_0001821 expression was an independent prognostic indicator for the poor OS. Furthermore, the expression of Caspase-3 protein was lower in patients with high circ_0001821 expression than that in those patients with low circ_0001821expression. Overexpression of circ_0001821 led to increased proliferation and arrested apoptosis of multiple myeloma cells, while knockdown of circ_0001821 had the opposite effects. Conclusion: High expression of circ_0001821 associated with aggressive pathological indicators and predicted a poor prognosis in multiple myeloma. Circ_0001821 played an oncogenic role in multiple myeloma by modulating cell proliferation and apoptosis.

show abstract

“…Yu et al reported that circ-MyBL2, as a tumor suppressor gene, affects tumor progression by inhibiting MM cell viability, DNA synthesis and cell cycle progression, and serves as a novel tumor marker [ 15 ]. Subsequently, with the advent of circ_0000142, circ-cdyl, and hsa_circRNA_101237 [ 16–18 ], infinite possibilities were provided for the prospect of MM treatment.…”

Section: Introductionmentioning

confidence: 99%

Serum hsa_circ_0087776 as a new oncologic marker for the joint diagnosis of multiple myeloma

et al. 2021

View full text Add to dashboard Cite

Multiple myeloma (MM) is a hematologic malignancy caused by abnormal proliferation of bone marrow plasma cells, which lacks diagnostic markers and has a general prognosis. At present, the understanding of its pathogenesis provides the basis for the combined diagnosis and new targeted therapy of the disease. In this study, quantitative real-time PCR was used to detect 136 MM patients and 74 healthy controls, and the clinical application value of hsa_circ_0087776 as a new tumor marker and combined diagnosis was evaluated. The results showed that the expression of hsa_circ_0087776 was significantly lower in serum of MM patients ( P -value < 0.0001), and the expression was consistent in MM cells. In the analysis of clinicopathological parameters, it was found that there were significant statistical differences with MM stage and renal injury. In addition, it significantly increased the sensitivity with ALB, β₂-MG joint diagnosis, to provide a basis for diagnosis, improve the prognosis of the disease, improve the survival of patients and quality of life. These studies suggest that hsa_circ_0087776 can be used as a new oncology marker for the combined diagnosis of MM. Impact statement: Various evidences have shown that the role of circRNA in the occurrence and development of diseases is potentially unknown and untapped. Therefore, it has a broad prospect to find circRNA specifically expressed in MM patients for combined diagnosis and targeted therapy of MM. However, MM lacks such specific tumor markers. Therefore, the discovery of new specific tumor markers for combined diagnosis is an important milestone in the development of medical history. In the research, we founded hsa_circ_0087776 can be used as a new oncology marker for combined diagnosis of MM.

show abstract

circRNA circ-MYBL2 is a novel tumor suppressor and potential biomarker in multiple myeloma

Cited by 23 publications

References 30 publications

A Cytoplasm-Enriched circRNA circ-MYBL2 is Downregulated in Non-Small Cell Lung Cancer and Sponges Oncogenic miR-28 to Regulate Cancer Cell Proliferation and Apoptosis

A Cytoplasm-Enriched circRNA circ-MYBL2 is Downregulated in Non-Small Cell Lung Cancer and Sponges Oncogenic miR-28 to Regulate Cancer Cell Proliferation and Apoptosis

CircRNA circ_0001821 predicts an unfavorable prognosis and promotes the proliferation of multiple myeloma

Serum hsa_circ_0087776 as a new oncologic marker for the joint diagnosis of multiple myeloma

Contact Info

Product

Resources

About